On this page
Vasoactive drug questions on the CCRN are rarely about arithmetic. They ask which drug fits the problem, what the drug does at the receptor, and which warning applies when something goes wrong at the bedside. This page puts those facts in one table, straight from each FDA label, and then tests them with 10 questions.
It is written for nurses using CCRN exam prep and pairs with the CCRN cardiovascular practice questions, which cover the rhythm drugs.
Doses are left out on purpose. This page is exam practice written from the FDA labels and guideline listed under References, not clinical guidance: follow the label, the prescriber's order and your institution's protocol. It has not been reviewed by a credentialed clinician or pharmacist.
The cheat sheet
| Drug | Action (per label) | Labeled use | Warning to know |
|---|---|---|---|
| Norepinephrine | Alpha-adrenergic vasoconstrictor; beta-adrenergic inotropic action | Raise BP in severe, acute hypotension | Infuse into a large vein; phentolamine infiltration for extravasation |
| Vasopressin | Vasoconstrictor | Vasodilatory shock still hypotensive despite fluids and catecholamines | Not a first-line agent by label wording |
| Epinephrine | Non-selective alpha and beta agonist | Raise MAP in hypotension from septic shock; anaphylaxis | Arrhythmia risk flagged by the Surviving Sepsis Campaign |
| Phenylephrine | Alpha-1 agonist | Hypotension from vasodilation during anesthesia | Severe bradycardia and decreased cardiac output |
| Dopamine | Catecholamine | Distributive shock or shock from reduced cardiac output | Phentolamine infiltration for extravasation |
| Dobutamine | Direct-acting inotrope via cardiac beta receptors | Short-term inotropic support in cardiac decompensation from depressed contractility | Tachycardia at higher rates |
| Milrinone | Phosphodiesterase inhibitor; inotrope and vasodilator | Short-term IV treatment of acute decompensated heart failure | ECG monitoring; life-threatening ventricular arrhythmias possible |
| Nitroprusside | Vasodilator | Immediate reduction of BP in hypertensive crises; controlled hypotension during surgery | Dilute before use; protect from light; cyanide toxicity |
| Nitroglycerin IV | Vasodilator | Labeled uses include angina not responding to sublingual nitroglycerin and beta blockers, and induced intraoperative hypotension | Adsorbs to PVC tubing; contraindicated in tamponade |
Practice questions
Question 1: A norepinephrine infiltration
The peripheral IV running norepinephrine is found infiltrated, and the skin around it is pale and cool. What does the Levophed label direct for the tissue?
- A. Infiltrate the ischemic area as soon as possible with phentolamine in saline
- B. Apply ice and elevate the arm only
- C. Inject hyaluronidase
- D. Restart the infusion at the same site at a lower rate
Best answer: A. The label says that to prevent sloughing and necrosis where extravasation has occurred, the ischemic area should be infiltrated as soon as possible with phentolamine diluted in 0.9% sodium chloride. Phentolamine blocks the alpha effect causing the vasoconstriction.
- B is not the best answer. Supportive measures alone do not reverse the alpha-mediated ischemia the label addresses.
- C is not the best answer. Hyaluronidase is not the antidote the label names.
- D is not the best answer. Restarting at the same infiltrated site continues the injury.
Question 2: Where to run it
Which administration instruction appears on the Levophed label?
- A. Give undiluted by IV push
- B. Infuse into a large vein, avoiding leg veins in the elderly or with occlusive vascular disease of the legs
- C. Infuse into a small hand vein to limit volume
- D. Use a catheter tie-in technique
Best answer: B. The label says to dilute before use, infuse into a large vein, avoid leg veins in the elderly or in patients with occlusive vascular disease of the legs, and avoid a catheter tie-in technique.
- A is not the best answer. The label says to dilute norepinephrine before use.
- C is not the best answer. The label directs a large vein, not a small one.
- D is not the best answer. The label says to avoid the catheter tie-in technique.
Question 3: What norepinephrine does
Which description of norepinephrine's action matches its label?
- A. Pure beta-1 agonist with no vascular effect
- B. Phosphodiesterase inhibitor
- C. Peripheral vasoconstrictor through alpha-adrenergic action, with inotropic stimulation of the heart through beta-adrenergic action
- D. Direct arterial vasodilator
Best answer: C. The label describes norepinephrine as a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
- A is not the best answer. Norepinephrine has a strong alpha vasoconstrictor effect.
- B is not the best answer. That describes milrinone.
- D is not the best answer. That describes nitroprusside.
Question 4: When vasopressin fits the label
Which patient matches the Vasostrict labeled indication?
- A. A patient with cardiogenic shock and a low cardiac index, as first agent
- B. A patient with hypovolemic shock before any fluid
- C. A patient with hypertensive emergency
- D. A patient in vasodilatory shock who remains hypotensive despite fluids and catecholamines
Best answer: D. The label indicates vasopressin to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The Surviving Sepsis Campaign similarly suggests adding it when MAP is inadequate on norepinephrine.
- A is not the best answer. The label is for vasodilatory shock, not low-output cardiogenic shock, and not as a first agent.
- B is not the best answer. The label requires that fluids have already been given.
- C is not the best answer. Vasopressin raises blood pressure. It has no role in a hypertensive emergency.
Question 5: A pure alpha agent and the heart rate
A patient on a phenylephrine infusion has a heart rate that falls from 88 to 46. Which label warning explains this?
- A. Phenylephrine can cause severe bradycardia and decreased cardiac output
- B. Phenylephrine causes reflex tachycardia only
- C. Phenylephrine blocks AV conduction directly
- D. Phenylephrine has beta-1 agonist effects
Best answer: A. The phenylephrine label warns it can cause severe bradycardia and decreased cardiac output. It is an alpha-1 agonist, so the rise in vascular resistance is not offset by beta stimulation of the heart.
- B is not the best answer. The label warns of bradycardia, not tachycardia.
- C is not the best answer. The label does not describe a direct AV-blocking action.
- D is not the best answer. The label describes phenylephrine as an alpha-1 adrenergic receptor agonist.
Question 6: Epinephrine in septic shock
Which statement about epinephrine matches its FDA label?
- A. It is a selective alpha-1 agonist used only for anaphylaxis.
- B. It is a non-selective alpha and beta agonist indicated to increase MAP in hypotension associated with septic shock, and for anaphylaxis.
- C. It is a vasodilator used for hypertensive crisis.
- D. It is a phosphodiesterase inhibitor.
Best answer: B. The label describes epinephrine as a non-selective alpha and beta adrenergic agonist, indicated to increase mean arterial pressure in adults with hypotension associated with septic shock and for emergency treatment of allergic reactions including anaphylaxis.
- A is not the best answer. Epinephrine is non-selective, and its label includes septic shock.
- C is not the best answer. Epinephrine raises blood pressure.
- D is not the best answer. That describes milrinone.
Question 7: Choosing an inotrope
A patient with depressed contractility and low cardiac output needs short-term inotropic support. Which drug's label describes it as a direct-acting inotrope working mainly through the heart's beta receptors?
- A. Phenylephrine
- B. Vasopressin
- C. Nitroglycerin
- D. Dobutamine
Best answer: D. The dobutamine label describes it as a direct-acting inotropic agent whose primary activity results from stimulation of the heart's beta receptors, indicated for short-term inotropic support in cardiac decompensation due to depressed contractility.
- A is not the best answer. Phenylephrine is an alpha-1 agonist and can decrease cardiac output.
- B is not the best answer. Vasopressin is a vasoconstrictor without inotropic labeling.
- C is not the best answer. Nitroglycerin is a vasodilator.
Question 8: Monitoring milrinone
A patient with acute decompensated heart failure is started on milrinone. What monitoring does the label require?
- A. None beyond daily weights
- B. Hourly blood glucose
- C. Close observation with ECG equipment and the ability to treat cardiac events, including life-threatening ventricular arrhythmias, immediately
- D. Serum cyanide levels
Best answer: C. The label says patients receiving milrinone should be observed closely with appropriate ECG equipment, and that facilities for immediate treatment of potential cardiac events, including life-threatening ventricular arrhythmias, must be available. Milrinone is a phosphodiesterase inhibitor with inotropic and vasodilator effects.
- A is not the best answer. The label requires ECG observation, not just weights.
- B is not the best answer. Glucose monitoring is not the label's requirement.
- D is not the best answer. Cyanide is a concern with nitroprusside, not milrinone.
Question 9: Preparing nitroprusside
Which preparation instruction comes from the sodium nitroprusside label?
- A. Give it by direct IV push
- B. Dilute it in 5% dextrose before infusion and protect the solution from light
- C. Mix it in the same line as blood products
- D. Store the infusion bag under a heat lamp
Best answer: B. The label states nitroprusside is not suitable for direct injection, must be further diluted in 5% dextrose before infusion, and must be protected from light in clinical use. It also warns that it can produce toxic, potentially lethal cyanide levels.
- A is not the best answer. The label says it is not suitable for direct injection.
- C is not the best answer. The label does not support co-infusion with blood products.
- D is not the best answer. Protection from light is required; heat is not part of the label.
Question 10: Nitroglycerin and the tubing
A nitroglycerin infusion seems to have less effect than expected. The tubing is a standard PVC set. What does the label warn?
- A. PVC tubing has no effect on nitroglycerin.
- B. PVC tubing makes nitroglycerin more potent.
- C. Nitroglycerin adsorbs to PVC tubing, so active drug is lost and dosing is affected.
- D. Nitroglycerin must be run with blood products.
Best answer: C. The label warns that PVC tubing may lead to loss of active ingredient because nitroglycerin adsorbs to PVC, so dosage is affected.
- A is not the best answer. The label says the opposite.
- B is not the best answer. Adsorption lowers the delivered dose; it does not raise potency.
- D is not the best answer. The label says nothing of the kind.
How do you choose between them on the exam?
Sort the problem first. Low vascular tone (sepsis, anesthesia) points to a vasoconstrictor; low contractility points to an inotrope; high pressure or high afterload points to a vasodilator. Then apply the drug's main warning: extravasation for norepinephrine and dopamine, bradycardia for phenylephrine, arrhythmias for milrinone, cyanide and light for nitroprusside, PVC tubing for nitroglycerin.
The Surviving Sepsis Campaign 2021 recommends norepinephrine as the first-line vasopressor in septic shock and flags arrhythmia risk with dopamine and epinephrine. For rhythm drugs such as adenosine, amiodarone and digoxin, see the CCRN cardiovascular practice questions, and for timed practice across the test plan, CCRN exam prep.
References
- [1] AACN Certification Corporation (2026). CCRN Exam Handbook, Direct Care (July 2026). AACN Certification Corporation. AACN Certification Corporation
- [2] FDA label (2026). Levophed (norepinephrine bitartrate). FDA label. FDA label
- [3] FDA label (2026). Vasostrict (vasopressin). FDA label. FDA label
- [4] FDA label (2026). Epinephrine injection. FDA label. FDA label
- [5] FDA label (2026). Phenylephrine hydrochloride injection. FDA label. FDA label
- [6] FDA label (2026). Dopamine hydrochloride injection. FDA label. FDA label
- [7] FDA label (2026). Dobutamine in 5% Dextrose Injection. FDA label. FDA label
- [8] FDA label (2026). Milrinone lactate injection. FDA label. FDA label
- [9] FDA label (2026). Sodium nitroprusside injection. FDA label. FDA label
- [10] FDA label (2026). Nitroglycerin in 5% Dextrose Injection. FDA label. FDA label
- [11] Surviving Sepsis Campaign (2021). International Guidelines for Management of Sepsis and Septic Shock 2021. Surviving Sepsis Campaign. Surviving Sepsis Campaign
Help us improve this guide
How helpful was this article?
One tap helps us understand what’s useful.
Frequently asked questions
Doses vary by product, indication, weight and protocol, and the CCRN tests decisions more than arithmetic. Use the label, the order and your unit's protocol for doses.
The Levophed label directs infiltrating the ischemic area as soon as possible with phentolamine diluted in normal saline.
Its label is for vasodilatory shock that stays hypotensive despite fluids and catecholamines. The Surviving Sepsis Campaign suggests adding it when MAP is inadequate on norepinephrine.
Dobutamine stimulates the heart's beta receptors. Milrinone is a phosphodiesterase inhibitor with inotropic and vasodilator effects. Both labels describe short-term use.
Its label states the solution is sensitive to certain wavelengths of light and must be protected from light in clinical use.
No. They are original PrepSolution practice items written from FDA labels and the Surviving Sepsis Campaign guideline. They have not been reviewed by a credentialed clinician or pharmacist and are not clinical guidance.
Keep practicing for the CCRN.
Review the study tools, access options and price, or start with free practice.
Related Articles
CCRN Cardiovascular Practice Questions: 13 With Rationales
Thirteen original CCRN cardiovascular questions on aortic dissection, atrial fibrillation, PSVT, cardiogenic shock and cardiac drugs, each keyed to a named guideline or FDA label.
CCRN Multisystem Practice Questions: Sepsis, Acid-Base, AKI and More
Twelve original CCRN multisystem questions on sepsis, vasopressors, DKA, anion gap, AKI, abdominal compartment syndrome, malignant hyperthermia and acetaminophen toxicity.
CCRN Exam Domains: What the New Test Plan Changed
AACN's new CCRN test plan took effect November 12, 2025. Cardiovascular fell from 17% to 13%, Respiratory from 15% to 12%, and Musculoskeletal/Neurological/Behavioral climbed from 14% to 18%. Here is every domain weight change and how to reprioritize your study plan.
